Time to rethink pharma reps?

docrepsPOST SUMMARY: 32% of physicians said they cannot talk to reps, compared to 27% last year. Apply this limit to doctors in organized health systems, and the restrictions become even greater: 42% of doctors affiliated with integrated health networks say they are not allowed to see reps—a 17% increase since last year.  Time for pharma to rethink reps? Continue reading »

Mobile apps for pharma: Opportunities exists

POST SUMMARY: Developing an app may not the answer for DTC marketers who want to improve bottom line results.  Apps require a lot of money to develop and most patients don’t want to be reminded that they have chronic health problems but there are opportunities for tose willing to blaze new trails NOW. Continue reading »

Will DTC marketers always be laggards?

laggardPOST SUMMARY:  Omnicom Media Group, the global media network that oversees more than $50 billion in annual ad spend for clients such as Apple, Starbucks, McDonald’s and Pepsi, is advising its clients to shift as much as 25% of their TV advertising budgets to online video. Will DTC marketers get the word or will we still be bombarded with drug commercials via the evening news? Continue reading »

60 Minutes slaps the drug industry

screenshot_19POST SUMMARY: The current model of the way cancer drugs are prices is unsustaianable and innovation is needed both to develop new drugs and price them in a way that ensures the drug is priced on “the value” it brings to patients. Continue reading »

Another week, more health news

drugcostsSen. Bernie Sanders and U.S. Rep. Elijah E. Cummings on Thursday launched an investigation into soaring generic drug prices. “We are conducting an investigation into the recent staggering price increases for generic drugs used to treat everything from common medical conditions to life-threatening illnesses,” Sanders, chairman of a Senate health care subcommittee, and Cummings, ranking member of the House oversight committee, wrote in letters to 14 pharmaceutical companies. Continue reading »

The perils of empowered patients

8-2POST SUMMARY: Not only do patients have to worry about which drug company paid their physician, they need to determine if their generic drug is the same as the branded equivalent and if their insurance company will allow their doctor to write for a specific medication.  What is pharma doing to help patients navigate the complex world of empowered patient choices? Continue reading »